CCO Treatment Updates
Clinical Strategies for Preventing and Managing Resistance to Anti-HBV Agents
Assessing HBV Virologic Markers
|
Module 1 of 10
|
- Stephen Locarnini, MD, PhD, FRC (Path)
|
|
|
 Dr. Stephen Locarnini reviews the various uses of DNA as an indicator of disease activity and as a prognostic marker in HBV infection Learning Objectives
Upon completion of this activity, participants should be able to:
- Describe the use of serum HBV DNA as a marker of disease progression in chronic hepatitis B
- Discuss assays for intrahepatic HBV DNA
- Review genotyping methods and trends in HBV genotypes
|
Role of HBV DNA in Patient Management
|
Module 2 of 10
|
- Geoffrey M. Dusheiko, MD, FCP(SA), FRCP
|
|
|
Dr. Geoffrey Dusheiko reviews how measures of HBV DNA can be used to assess individual HBV-infected patients. Learning Objectives
Upon completion of this activity, participants should be able to:
- Discuss HBV serologic markers in terms of the natural history of hepatitis B and disease stage
- Review prognostic factors relating to hepatitis B disease severity and progression
- Discuss the development of HBV drug resistance
|
Definitions of HBV Treatment Failure and Resistance
|
Module 3 of 10
|
- Jean-Michel Pawlotsky, MD, PhD
|
|
|
Dr. Jean-Michel Pawlotsky reviews current definitions of HBV treatment failure and resistance Learning Objectives
Upon completion of this activity, participants should be able to:
- Review virologic treatment endpoints and define treatment efficacy and failure in the setting of HBV infection
- Discuss HBV resistance variants
- Discuss the use of anti-HBV drugs in clinical practice
|
Natural History of Hepatitis B Virus Infection
|
Module 4 of 10
|
|
|
|
Dr. Paul Martin reviews current demographic trends of HBV infection in the Western world, as well as the emergence of mutant forms of the virus. Learning Objectives
Upon completion of this activity, participants should be able to:
- Detail the global distribution and prevalence of HBV infection
- Define the natural history of chronic hepatitis B
- Discuss various outcomes of HBV infection
|
Natural History of Chronic HBV Infection in Patients Receiving Anti-HBV Therapy
|
Module 5 of 10
|
|
|
|
Dr. George K.K. Lau discusses current knowledge of the natural history of chronic HBV infection in patients receiving anti-HBV drugs. Learning Objectives
Upon completion of this activity, participants should be able to:
- Discuss the natural history of both treated and untreated chronic HBV infection
- Review long-term outcomes of HBV treatment with nucleotide analogues or interferons
- Compare and contrast various combinations of interferons and nucleotide analogues in the treatment of chronic hepatitis B
|
Outcomes After HBV Treatment Failure Due to Resistance
|
Module 6 of 10
|
- Daryl T-Y Lau, MD, MSc, MPH, FRCP(C)
|
|
|
Dr. Daryl T. Lau reviews HBV resistance to lamivudine, entecavir, and adefovir. Learning Objectives
Upon completion of this activity, participants should be able to:
- Review HBV resistance to lamivudine treatment
- Discuss resistance to adefovir in the treatment of hepatitis B
- Discuss entecavir use and resistance in chronic HBV infection
|
Contending With HBV Resistance: Lessons Learned From HIV Resistance and Its Management
|
Module 7 of 10
|
|
|
|
Dr. Douglas R. Richman applies lessons from HIV management to management of patients infected with drug-resistant strains of HBV. Learning Objectives
Upon completion of this activity, participants should be able to:
- Compare and contrast HBV and HIV infections
- Discuss strategies to combat HBV drug resistance
- Discuss antiviral drugs and their potency in the HBV infection setting
|
Translating Lessons Learned with HIV Resistance Assays Into Tools for Hepatitis B Virus Resistance Treatment
|
Module 8 of 10
|
|
|
|
Dr. Angelos Hatzakis reviews technologies used in treating drug-resistant HIV for their applicability in HBV treatment. Learning Objectives
Upon completion of this activity, participants should be able to:
- Review HIV virologic resistance assays that could be used in the treatment of chronic hepatitis B
- Explain how knowledge gained from HIV phenotyping assays might be applied in the chronic hepatitis B setting
- Discuss HIV drug resistance testing recommendations in the United States and Europe
|
Summary of Mutations Associated With Resistance to HBV Drugs
|
Module 9 of 10
|
|
|
|
Dr. Jake Liang reviews HBV mutations that confer resistance to nucleos(t)ide analogues. Learning Objectives
Upon completion of this activity, participants should be able to:
- Review nucleos(t)ide analogue drug resistance mutations in HBV polymerase
- Define the 3 groups of nucleos(t)ide analogues used in the treatment of HBV infection
- Discuss cross-resistance to anti-HBV drugs
|
Tools for the Assessment of HBV Resistance in Clinical Practice
|
Module 10 of 10
|
|
|
|
Dr. Fabien Zoulim describes assays for HBV drug resistance. Learning Objectives
Upon completion of this activity, participants should be able to:
- Discuss viral load monitoring in chronic hepatitis B patients
- Summarize the development of HBV drug resistance
- Describe strategies to monitor drug resistance evolution in chronic HBV infection
|
Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.
|
Jointly sponsored by Postgraduate Institute for Medicine and Clinical Care Options, LLC.
Contact Info
Educational grant provided by:
Educational grants support only the CME-certified components of this program.
|